4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]-

Request For Quotation
4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]- Suppliers list
Company Name: ChemCell Biomedicine Co.,Ltd.  
Tel: 020-13556033878 2965585218 13556033878
Email: chemcell@hotmail.com
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 13816613772
Email: huahero21@sina.com
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Shanghai Hongye Biotechnology Co. Ltd  
Tel: 400-9205774 400-920-5774
Email: sales@glpbio.cn

4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]- manufacturers

  • Vamifeport
  • Vamifeport pictures
  • $64.00
  • 2026-08-30
  • CAS:2095668-10-1
  • Purity: 99.91%
  • Supply Ability: 10g
4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]- Basic information
Product Name:4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]-
Synonyms:4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]-;Vamifeport, 10 mM in DMSO;2-(2-((2-(1H-Benzo[d]imidazol-2-yl)ethyl)amino)ethyl)-N-((3-fluoropyridin-2-yl)methyl)oxazole-4-carboxamide;VIT-2763;Vamifeport;2-[2-[[2-(1H-Benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]-4-oxazolecarboxamide (ACI)
CAS:2095668-10-1
MF:C21H21FN6O2
MW:408.43
EINECS:
Product Categories:
Mol File:2095668-10-1.mol
4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]- Structure
4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]- Chemical Properties
Boiling point 727.8±60.0 °C(Predicted)
density 1.339±0.06 g/cm3(Predicted)
pka11.87±0.46(Predicted)
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]- Usage And Synthesis
UsesVIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia[1].
in vivo

VIT-2763 (30, 100 mg/kg, orally twice daily for 36 days) decreases serum iron and prevented liver iron loading in Hbbth3/+ mice[1].
VIT-2763 did not change the total liver iron[1].
VIT-2763 (30, 100 mg/kg, orally twice daily for 36 days) significantly corrects anemia and improved RBC parameters in Hbbth3/+ mice. VIT-2763 decreases the percentage of ROS-positive RBCs in Hbbth3/+ mice from 67% to 30%[1].
VIT-2763 decreases apoptosis and extends the life span of RBCs in Hbbth3/+ mice[1].

Animal Model:Hbbth3/+ mice[1].
Dosage:30, 100 mg/kg.
Administration:Orally twice daily for 36 days.
Result:Significantly decreased serum iron levels by 77% (30 mg/kg) and 84% (100 mg/kg),
Significantly increased Hb levels (as of day 8 of treatment), RBC counts, mean corpuscular Hb concentration (MCHC), and significantly lowered reticulocyte counts, mean corpuscular Hb (MCH), mean corpuscular volume (MCV), and RBC distribution width (RDW) in Hbbth3/+ mice, as compared with the Hbbth3/+ vehicle group.
References[1] Vania Manolova, et al. Oral Ferroportin Inhibitor Ameliorates Ineffective Erythropoiesis in a Model of β-Thalassemia. J Clin Invest. 2019 Dec 9;130(1):491-506. DOI:10.1172/JCI129382
4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]- Preparation Products And Raw materials
Tag:4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]-(2095668-10-1) Related Product Information
4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]-, hydrochloride (1:1) 4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]-, hydrochloride (1:3) 4-Oxazolecarboxamide, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-N-[(3-fluoro-2-pyridinyl)methyl]- L-Lysinamide, N-(3-methyl-1-oxobutyl)-L-α-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-L-cysteinyl-L-isoleucyl-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-L-lysyl-L-phenylalanyl-L-α-glutamyl-L-prolyl-L-arginyl-L-seryl-L-lysylglycyl-L-cysteinyl-, cyclic (6→16)-disulfide Thiazolo[5,4-d]pyrimidin-5(4H)-one, 2-[2-[[2-(1H-benzimidazol-2-yl)ethyl]amino]ethyl]-7-[[(3-fluoro-2-pyridinyl)methyl]amino]- Fursultiamine